Health Technology Assessment on the role of vaccination against human papillomavirus in reducing the risk of cervical cancer in Ireland.
In February 2008, the NCPE completed the HTA of the human papillomavirus (HPV) vaccine in Ireland, on behalf of the Health Information and Quality Authority (HIQA). A summary of the main findings are available in the attached document.
Economic Evaluation of a Universal Meningitis B Vaccination Programme in Ireland
In February 2014, the National Centre for Pharmacoeconomics completed the evaluation of the cost-effectiveness of a universal meningitis B vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document.
Cost effectiveness analysis of a universal infant pneumococcal conjugate vaccination programme in Ireland.
In March 2007, the National Centre for Pharmacoeconomics evaluated the cost-effectiveness of a universal pneumococcal conjugate vaccination programme in Ireland. A summary of the main findings are available in the attached document.
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland.
In January 2010, the National Centre for Pharmacoeconomics completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document.
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
In October 2006, the National Centre for Pharmacoeconomics conducted an economic evaluation of the cost-effectiveness of a universal hepatitis B vaccination programme, for the Health Protection Surveillance Centre/National Immunisation Advisory Committee. A summary of the main findings are available in the attached document.
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
In October 2006, the National Centre for Pharmacoeconomics conducted an economic evaluation of the cost-effectiveness of a universal hepatitis B vaccination programme, for the Health Protection Surveillance Centre/National Immunisation Advisory Committee. A summary of the main findings are available in the attached document.
